Background: Axl is a receptor tyrosine kinase that is involved in many pathological conditions and carcinogenesis. Gas6 is the major ligand of Axl. Activation of Gas6/Axl pathway is essential for cancer development. However, its prognostic significance in solid tumors remains unclear. Therefore, we performed this meta-analysis to elucidate the prognostic impact of Axl. Methods: Published studies on Axl or Gas6 expression and overall survival (OS) and/or disease-free survival (DFS) were searched from databases. The outcome measurement is hazard ratio (HR) for OS or DFS related to Axl/Gas6 expression. Meta-analysis was performed using RevMan. The pooled HR was calculated by fixed-/random-effect models. Results: A total of 3,344 patients from 25 studies were included. The results of meta-analysis showed that Axl overexpression was correlated with shorter OS (HR: 2.03, p,0.0001) and DFS (HR: 1.85, p,0.0001). In subgroup analysis, Axl expression was significantly correlated with poor prognosis in hepatocellular, esophageal and lung cancer. Axl expression was associated with differentiation grade, TNM stage, lymph node and distant metastasis. Conclusion: These results suggest that Axl overexpression is correlated with poor prognosis in solid tumors. This correlation varies among different types of cancers. More studies are needed to further investigate the prognostic value of Axl. Keywords: Gas6/Axl, prognosis, solid tumor, biomarker, meta-analysis, overall survival, disease-free survival
Introduction
As a life-threatening disease, cancer is a major contributor to health care burden and increased human mortality. 1 Multiple sequential genetic and epigenetic changes are involved in the process of carcinogenesis. The activation of Gas6/Axl signaling pathway has been found to play an important role during the process of cancer development and progression. The receptor tyrosine kinase Axl belongs to TAM (Tyro3, Axl and Mertk) family and is characterized by an extracellular domain consisting of 2 immunoglobulin-like domains in juxtaposition to 2 fibronectin type III domains, typical for cell adhesion molecules of the immunoglobulin superfamily. [2] [3] [4] Axl plays a pivotal part in various physiological and pathological processes. When bound to its ligand Gas6, the activated Axl will induce the multiple downstream pathways and lead to resistance of apoptosis, and increased migration and growth. 5 Upregulation of Gas6/Axl pathway has been found highly related to carcinogenesis. 5 The overexpression of Axl has been underlined in several conditions especially in carcinogenesis. It has been found that Axl is overexpressed in various cancers such as breast cancer, lung cancer and gastrointestinal malignancies. Overexpression of Axl is reported to correlate with poor prognosis. 5 These evidences suggest that Axl could be considered as a potential biomarker for evaluating prognosis in cancer patients.
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Although many anti-Axl inhibitors have been developed and launched into Phase I and II clinical trials and have showed some promising results, the comprehensive prognostic value of Gas6/Axl in solid tumors is still not clear. 6 Therefore, we performed this meta-analysis and sought to evaluate the association between Axl expression and prognostic factors including overall survival (OS) and disease-free survival (DFS) in patients with solid tumors. The results of our meta-analysis may provide high-level evidences to verify the prognostic effect of Axl in solid cancers.
Methods search strategy and eligible studies
We performed a comprehensive search of the electronic databases including PubMed, Embase, the Cochrane Library and Web of Science, using the keywords "solid tumor OR cancer OR carcinoma OR neoplasm" AND "Axl OR Gas6
OR ARK OR Tyro7 OR UFO OR AXL receptor tyrosine kinase" AND "prognosis". Both titles and abstracts were carefully screened by 2 independent reviewers to exclude irrelevant studies. Duplicate studies were removed, and additional studies were identified by a manual search of references cited in the original studies. If different studies on same patient population were identified, only the one with the largest patient number was included based on the updated PRISMA criteria. 7 A flow chart of the search process is presented in Figure 1 .
inclusion and exclusion criteria
To be eligible for inclusion in this meta-analysis, a study was required to meet the following inclusion criteria: (1) published in English and full text is accessible; (2) provided survival information such as relapse-free survival (RFS) and OS associated with Axl or Gas6 expression; (3) participants 
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Prognostic role of gas6/axl axis in solid malignancies must have had a solid tumor; (4) the study should provided hazard ratio (HR) and 95% confidence interval (CI), or data that could be used to estimate the HRs and 95% CIs, or Kaplan-Meier survival curves with sufficient data to extract HRs and 95% CIs; and (5) the study must be a peer-reviewed and published original article. Exclusion criteria: (1) review articles, case reports, letters, comments or book chapters, and studies that had (2) no data on survival or RFS or (3) insufficient data for calculation of HRs.
Data extraction and quality assessment
According to the inclusion and exclusion criteria, 2 reviewers (SZ and YXT) searched and assessed the studies independently. Studies were chosen by consensus. The following items were extracted from each study: author, publication year, country, patient number, follow-up period, patient clinicopathological features, Axl/Gas6 detection method, cut-off criteria, statistical method and HR of OS and/or DFS. If HR was not available, we applied GetData Graph Digitizer 2.3 to digitize and extract survival information from the Kaplan-Meier curves. Manual calculation methods were also applied to estimate the HR and 95% CI according to the literature. 8 Quality assessment of the included studies was performed by 2 independent reviewers (XSX and JXY) according to REMARK (REporting recommendations for tumor MARKer prognostic studies) guideline. 9 As previously published, 10 we used the 20-item scale for quality assessment (Table 1 ). In brief, this scale includes information on study design, assay method, outcomes and statistical analysis method. Each item is scored as follows: 2 points if it is clearly indicated, 1 point if the description is partial or unclear and 0 point if it is not mentioned in the study. Higher scores represent better quality of the original study.
statistical analysis
Cochrane RevMan 5.3.0 (The Cochrane Collaboration, London, UK) was applied for meta-analysis. Individual HRs and 95% CIs were combined from individual studies to determine the overall effective value of Axl and Gas6. For the overall result, an observed HR .1 implied that Axl/Gas6 overexpression was a risk factor for OS. The χ 2 test was used to evaluate heterogeneity between studies. A p-value ,0.05 indicated that the heterogeneity between individual studies was statistically significant. The total variation among studies was estimated by I
2 . An I 2 value ,25% suggested low heterogeneity, and fixed-effects model was used. If heterogeneity was significant, a combined HR was 
Results
search results and characteristics of the eligible studies
In total, 544 studies were identified by our search, of which 110 articles were from PubMed and 434 were from other databases (Figure 1) . After removing duplicate studies and screening of titles and abstracts, 43 articles were found to be potentially eligible for our meta-analysis. Eventually, 25 studies fulfilled our inclusion criteria. Among the included articles, 22 studies [14] [15] [16] [17] [18] [19] [20] [21] [22] [24] [25] [26] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] had available data to analyze the association between Axl expression and OS, 13 studies 14, 18, 21, 22, [27] [28] [29] 31, [33] [34] [35] [36] [37] had available data to analyze the association between Axl expression and DFS and 7 studies [13] [14] [15] [22] [23] [24] 32 contained data on Gas6 expression and its relation with OS.
Together, the 25 eligible studies involved 3,344 patients with solid tumor. The sample size of included cohorts ranged from 35 to 509, with a median of 88 patients. In terms of cancer type, 4 studies evaluated breast cancer, followed by hepatocellular carcinoma (n=2), esophageal cancer (n=2), lung cancer (n=2) and other cancer types (glioblastoma multiforme, renal cell carcinoma, pancreatic cancer, oral squamous cell carcinoma (OSCC), ovarian adenocarcinoma, osteosarcoma, nasopharyngeal carcinoma, colorectal cancer, etc). Other information of included studies is summarized in Table 2 .
correlation of axl expression and Os in all solid tumor patients As shown in Figure 2 , on pooling data of correlation between OS and Axl expression from 22 studies (3,170 patients), the combined HR was calculated to be 2.03 (95% CI (Figure 3A-D) .
impact of axl expression on DFs in all solid tumor patients
We analyzed the impact of Axl expression on DFS in all solid tumor patients with available data. From 13 studies, the combined HR for impact of Axl overexpression on DFS was 1.85 (1,585 patients, 95% CI 1.44-2.38, p,0.00001), which indicated that the overexpression of Axl increases the risk of disease recurrence by 1.85-fold (Figure 4) . No significant heterogeneity was detected among studies (I 2 =37%, p=0.09).
impact of gas6 expression on Os in all solid tumor patients
The correlation of OS and Gas6 expression was analyzed in 7 studies with a total of 807 patients. As illustrated in Figure 5 , the combined HR was 1. (Figure 6A-D) .
assessment of publication bias
We evaluated the publication bias of the correlation between Axl expression and OS and DFS. As shown in Figure 7A and B, the funnel plots were symmetrical. In addition, Egger's test showed no significant publication bias in meta-analysis of 
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Discussion
It has been widely studied and proved that the activation of Gas6/Axl pathway is implicated in the development and progression of cancer. The activation of Axl is dependent on its overexpression as it has been found overexpressed in various malignancies 5 and related to poor prognosis. To the best of our knowledge, this meta-analysis is the first and most comprehensive study to systematically explore the impact of Axl and Gas6 expression on prognosis in various solid malignancies.
In the present study, we included 25 studies with 3,344 patients and analyzed whether Axl is a significant prognostic risk factor in solid tumors. In general, Axl was overexpressed in cancerous tissue compared to normal control tissue (average: 54.7% vs 12.7%) (Table S1 ). First, we analyzed the overall impact of Axl expression on OS from 22 studies. Our results demonstrated that Axl overexpression significantly correlated with a 2.03-fold (95% CI 1.73-2.37) increase in mortality in all solid tumor patients.
In terms of DFS, the meta-analysis of 13 studies indicated that overexpression of Axl was significantly correlated with a shorter DFS time, with a pooled HR of 1.85 (95% CI 1.44-2.38). No significant heterogeneity and publication bias were detected among studies, which suggested that our results of Axl overexpression indicating poor OS and DFS are convincing. As Axl expression was relatively high in cancerous tissue (54.7%) compared to normal counterpart (12.7%), Axl can be used as a sensitive and potent indicator for predicting outcome of solid malignancies.
Furthermore, we stratified the results by different cancer types. Our subgroup analysis showed that Axl overexpression was correlated with decreased OS in hepatocellular carcinoma (OR: 1.89, 95% CI 1.37-2.60), esophageal cancer (OR: 1.99, 95% CI 1.28-3.11) and lung cancer (OR: 1.67, 95% CI 1.04-2.67). The subgroup results are in concordance with previous in vitro data. In hepatocellular cancer cell lines, Gas6/Axl can enhance cell invasiveness through transcriptional activation of Slug which induces epithelialmesenchymal transition (EMT). 38 Studies also found that Axl overexpression correlated with enhanced cell motility and invasiveness in lung cancer. 39 In addition, activation of Axl could cause resistance of EGFR-targeted therapy in lung cancer. 40 In esophageal cancer, it has been shown that genetic silencing of Axl can inhibit proliferation, migration 
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Prognostic role of gas6/axl axis in solid malignancies and invasion. 41 Although many studies provided substantial evidences of Axl's biological significance in breast cancer development, [42] [43] [44] our meta-analysis failed to show significant correlation between Axl expression and OS in breast cancer patients. More translational studies are needed to further explore the role of Axl signaling pathway in breast cancer.
Clinical parameters such as differentiation grade, lymph node involvement, distant metastasis and TNM stages are critical factors to predict outcomes in solid tumors. Studies have demonstrated that Gas6/Axl pathway activation could initiate EMT process and enhance cancer cell invasiveness. 45 In our meta-analysis, we evaluated the relationship between Axl expression and various clinicopathological characteristics.
Our results indicated that poor differentiation (OR: 1.95, 95% CI 1.29-2.97), advanced TNM stage (OR: 2.81, 95% CI 1.65-4.80), positive lymph node metastasis (OR: 2.99, 95% CI 1.54-5.79) and positive distant metastasis (OR: 4.14, 95% CI 2.20-7.79) are correlated with Axl overexpression. These findings suggest that Axl could serve as a valuable predicting factor in solid tumors.
As the major ligand of Axl, Gas6 may activate Axl signaling pathway and initiate its downstream events. Researchers have found that Gas6 is overexpressed in certain cancers compared to normal adjacent tissues 46 and can enhance cancer cell viability and motility in vitro. 47 Jiang et al also proved that in OSCC patients, serum Gas6 level is elevated 
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Zhang et al and it can be an independent factor to predict prognosis (HR from multivariate analysis: 2.07, p,0.05). 48 Due to limited number of included studies, our meta-analysis of relationship between Gas6 expression and OS showed no statistical significance. However, we noted that there is significant heterogeneity between studies (I 2 =58%). We therefore conducted the sensitivity examination by deleting single study from the meta-analysis and found that if the study by Akitake-Kawano et al 23 was removed, the pooled HR for the effect of Gas6 overexpression on OS would be 1.44 (95% CI 1.02-2.04, p=0.04) and the heterogeneity was eliminated (I 2 =27%) ( Figure S1 ). This discrepancy might be due to the following possibility: (1) insufficient studies were included; (2) heterogeneity between different types of solid tumors was poor; and (3) Gas6 has a complex pathophysiological role. Unlike Axl, Gas6 is a secreted protein that is usually released into circulation. In terms of cancer development, it is still not clear whether tumor tissues secrete Gas6 to facilitate cancer cell proliferation or other stromal cells secrete Gas6 to support tumor growth. To answer this question, more studies are needed to elucidate the underlining mechanism.
According to our comprehensive quality assessment system, all included studies had moderate-to high-quality scores (Table S2) . Apart from the animating results, there are several limitations of this meta-analysis. First, although it included various types of cancers, there is limited number of studies for each specific cancer type. It is inconclusive whether Axl expression correlates with OS in a specific type of cancer. Second, impact of Gas6 expression on OS is still inconclusive. Gas6 and Axl expression might be detected together in future study to explore whether it is more accurate in predicting outcome. Third, different staining protocols, reagents and cut-off evaluation were applied in individual studies. This heterogeneity was difficult to eliminate which may generate bias in the overall result. Finally, although random-effect model was applied, heterogeneity between studies still existed 
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Zhang et al Figure 7 Funnel plots of hr of axl expression for Os (A) and DFs (B) in all solid tumor patients. Abbreviations: DFs, disease-free survival; hr, hazard ratio; ln, natural logarithm; Os, overall survival; se, standard error.
and this may affect the overall result. Thus, more high-quality studies are needed to draw more reliable conclusions.
In spite of the limitations mentioned above, this comprehensive meta-analysis has many valuable implications. First, the present study evaluated for the first time the prognostic value of Axl expression in all solid tumor patients. We demonstrated and validated that Axl is a prognostic factor for unfavorable outcome in solid tumor. Second, we also proved that Axl overexpression is correlated with clinical parameters such as advanced stage, poor differentiation grade, lymph node metastasis and distant metastasis. In conclusion, according to our meta-analysis, Axl is a promising biomarker for predicting prognosis in solid tumor. Our results may provide evidence for further research on biological role of Gas6/Axl axis in a specific type of cancer.
